Related Experiment Video
Updated: Jan 30, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Invasive aspergillosis complicating treatment with tyrosine kinase inhibitors
Tajwar Nasir1, Claudia Lee1, Alexandra Sc Lawrence2
1Respiratory Division of Medicine, University College London Medical School, London, UK.
Abstract:
We describe three cases of pulmonary aspergillosis (PA) in three patients without traditional risk factors for invasive aspergillosis infection, such as prolonged neutropenia or high dose systemic corticosteroid therapy. All three patients developed PA while taking tyrosine kinase inhibitors (TKI) and sustained greater clinical improvement once TKI were withdrawn. Our case series supports the theory TKI treatment can increase susceptibility to PA without causing neutropenia. Recognition that TKI treatment may predispose to invasive aspergillosis will allow for rapid recognition of affected patients and more effective management of future cases.
Insights
Tyrosine kinase inhibitors (TKI) may increase susceptibility to pulmonary aspergillosis (PA) in patients lacking traditional risk factors. Withdrawing TKI treatment led to clinical improvement, suggesting a link between TKI use and PA risk.
Area of Science:
- Pulmonology
- Infectious Diseases
- Oncology
Background:
- Pulmonary aspergillosis (PA) typically affects immunocompromised individuals.
- Traditional risk factors include neutropenia and high-dose corticosteroid use.
Observation:
- Three patients developed PA without typical risk factors.
- All patients were undergoing treatment with tyrosine kinase inhibitors (TKI).
Findings:
- PA onset correlated with TKI therapy.
- Discontinuation of TKI resulted in significant clinical improvement.
- TKI may increase susceptibility to PA independently of neutropenia.
Implications:
- TKI treatment could be an emerging risk factor for invasive aspergillosis.
- Early recognition of PA in TKI-treated patients is crucial.
- This finding may alter management strategies for TKI-associated PA.
More Related Videos
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
08:01Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Receptor Tyrosine Kinases
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...